MediXall Group (NASDAQ: MDXL) files notification of delinquent 10-K/10-Qs

Rhea-AI Filing Summary

MediXall Group, Inc. filed a Form 12b-25 notifying the SEC of a late annual report for the period ended December 31, 2025. The company cites that certain financial and other information could not be provided without "unreasonable effort or expense" and states it is delinquent in its 2024 Form 10-K and three 2025 Form 10-Qs. The notice is signed by Travis Jackson, CFO on March 31, 2026.

Key Figures

Period Ended: December 31, 2025 Delinquent Filings: 2024 Form 10-K; 10-Qs for Mar 31, Jun 30, Sep 30 2025 Notification Date: March 31, 2026 +1 more

4 metrics

Period Ended December 31, 2025 subject report period end

Delinquent Filings 2024 Form 10-K; 10-Qs for Mar 31, Jun 30, Sep 30 2025 identified delinquent reports

Notification Date March 31, 2026 date the Form 12b-25 was signed

Contact Phone 800-381-1787 contact for notification

Key Terms

Form 12b-25, unreasonable effort or expense, delinquent

3 terms

Form 12b-25 regulatory

"NOTIFICATION OF LATE FILING (Form 12b-25)"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

unreasonable effort or expense regulatory

"could not be provided within the prescribed time period without unreasonable effort or expense"

delinquent other

"The Company is delinquent in filing the 2024 Form 10-K"

	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
		FORM 12b-25	SEC FILE NUMBER 333-194337
		NOTIFICATION OF LATE FILING	CUSIP NUMBER

(Check one): ü  Form 10-K   Form 20-F   Form 11-K   Form 10-Q   Form 10-D   Form N-CEN   Form N-CSR

	For Period Ended:		December 31, 2025
		Transition Report on Form 10-K
		Transition Report on Form 20-F
		Transition Report on Form 11-K
		Transition Report on Form 10-Q
	For the Transition Period Ended:

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

MediXall Group, Inc.

Full Name of Registrant

Former Name if Applicable

104 N 4th St.

Address of Principal Executive Office (Street and Number)

Leesburg, FL 34748

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

				(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
				(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	ü
						(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

Certain financial and other information necessary for an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort or expense.

PART IV — OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification
	Travis Jackson		800		381-1787
	(Name)		(Area Code)		(Telephone Number)
(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes							No	ü
	The Company is delinquent in filing the 2024 Form 10-K and the Form 10-Q for the periods ended March 31, 2025, June 30, 2025 and September 30, 2025. We are in the process of preparing the respective Form 10-Q’s for filing with the Securities and Exchange Commission.
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes							No	ü
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

	MediXall Group, Inc.
	(Name of Registrant as Specified in Charter)
	has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:		March 31, 2026			By:	/s/ Travis Jackson
						Travis Jackson, Chief Financial Officer

FAQ

Why did MediXall Group (MDXL) file a Form 12b-25?

MediXall filed Form 12b-25 because certain financial and other information required for an accurate report could not be completed without unreasonable effort or expense. The filing explains the company needs extra time to prepare the affected reports and attaches a narrative signed by the CFO.

Which specific filings is MDXL delinquent in according to the notice?

The notice states delinquency for the 2024 Form 10-K and the Form 10-Qs for periods ended March 31, 2025, June 30, 2025, and September 30, 2025. The company says it is preparing the respective Form 10-Qs for filing with the SEC.

Does the Form 12b-25 state whether MediXall expects material changes in results?

The company answered "No" to anticipating significant changes in results of operations compared with the prior year. The notice therefore does not attach narrative or quantitative estimates of material changes to earnings for the subject reporting periods.

Who is the contact for this notification and when was it signed?

The notification lists Travis Jackson, Chief Financial Officer, as the contact with phone number ending in 1787. The Form 12b-25 is signed and dated March 31, 2026 by Travis Jackson on behalf of the company.